search
Back to results

Study of ASN004 in Patients With Advanced Solid Tumors (ASN004)

Primary Purpose

Solid Tumor

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
ASN004
Sponsored by
Kirilys Therapeutics Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Solid Tumor focused on measuring antibody-drug conjugate, immunoconjugate, General Solid Tumors

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

  1. Provide written, voluntary informed consent prior to any -study specific procedure.
  2. Histologically confirmed diagnosis of advanced malignant solid tumor.
  3. All patients must be willing to undergo tumor biopsy, preferably of the primary tumor, within 28 days prior to Cycle 1 Day 1. If the Investigator determines that the tumor is inaccessible for biopsy, archived tumor material collected within the last 12 months may be submitted.
  4. Evidence of progressive disease.
  5. Minimum life expectancy of at least 3 months, in the judgment of the Investigator.
  6. Failure of standard therapy or no standard therapy available.
  7. Presence of at least 1 measurable target lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 excluding previously irradiated lesions, bone metastasis, or pleural effusion as sole manifestations of disease.
  8. Patient's most recent therapy must have been completed within the following limits prior to the first dose of study drug:

    1. prior cytotoxic chemotherapy treatments at least 3 weeks prior to first dose of study drug.
    2. Completion of prior targeted anticancer treatments at least 2 weeks or 5 -half-lives prior to first dose of study drug, whichever is longer.
    3. Completion of prior immuno-oncology treatments at least 3 weeks prior to first dose of study drug.
  9. Patients must have recovered from any AE related to prior anticancer therapy to Grade 1 or less except for alopecia.
  10. Age of at least 18 years old.
  11. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  12. A male patient must agree to use contraception as detailed in this protocol during the treatment period and for at least 3 months after the last dose of study treatment and refrain from donating sperm during this period.
  13. A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies.

    i. Not a woman of childbearing potential (WOCBP) OR ii. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 3 months after the last dose of study treatment.

  14. Adequate organ function as determined by the following criteria:

    1. Hemoglobin ≥ 9.0 g/dL.
    2. Absolute neutrophil count ≥ 1.5 × 109/L.
    3. Platelet count ≥ 100 × 109/L.
    4. Serum creatinine ≤ 1.5 × upper limit of normal (ULN) AND calculated creatinine clearance of > 60 mL/min.
    5. Aspartate aminotransferase (AST; serum glutamic oxaloacetic transaminase) and alanine aminotransferase (ALT; serum glutamic-pyruvic transaminase) ≤ 3× ULN (or ≤ 2.5 × ULN if liver metastases).
    6. Total bilirubin ≤ 1.5 x ULN.
    7. Albumin ≥ 2.5 g/dL.
    8. Activated partial thromboplastin time, prothrombin time, and international normalized ratio within normal limits unless anticoagulated for VTE treatment/prophylaxis at stable dose.
  15. Patient is willing and able to comply with all protocol required visits and assessments.

Exclusion Criteria

  1. Hematologic malignancies and lymphomas.
  2. Known hypersensitivity to ASN004, its components, or its excipients.
  3. Prior allergic reaction to recombinant human or murine proteins or known history of human anti-human or anti-murine antibody formation.
  4. Known central nervous system (CNS) metastasis.
  5. Known bleeding diathesis.
  6. History of or active hepatitis B or hepatitis C infection.
  7. Major surgery within 30 days prior to the start of study medication.
  8. Infection requiring intravenous antibiotics within 14 days prior to the start of study medication.
  9. Serious concurrent medical conditions, such as:

    1. Clinically significant history of cardiovascular disease such as congestive heart failure New York Heart Association Class III or IV or uncontrolled hypertension at Screening.
    2. 12-Lead electrocardiogram (ECG) abnormalities considered by the Investigator to be clinically significant including QTcF ≥ 450 milliseconds at Screening (abnormal ECG confirmed by repeat assessment).
    3. Severe dyspnea at rest or requiring oxygen therapy.
    4. Active pneumonitis or interstitial lung disease.
    5. Biliary obstruction, biliary blockage, and biliary stents.
  10. Radiation therapy exceeding more than 5 Gray to the mediastinum/heart.
  11. Patients with known history of left ventricular ejection fraction of < 50%.
  12. Receipt of any investigational treatment within 4 weeks prior to the start of study medication.
  13. Any previous treatment with antibody drug conjugate (ADC).
  14. Prior participation, i.e., receipt of study medication, in this study.
  15. Any condition that may impair the patient's ability to comply with study procedures or impact that ability to interpret study results.
  16. Active and clinically significant bacterial, fungal, and viral infection such as immunodeficiency virus.
  17. Female patients who are pregnant or breastfeeding or intend to become pregnant during their participation in the study or male patients who intend to father a child during their participation in the study.
  18. History of another invasive malignancy that has not been in remission for at least 2 years. Exceptions to the -2-year limit include non-melanoma skin cancer, ductal carcinoma in situ, and cervical cancer in situ.
  19. Any medical history, laboratory, imaging, ECG, or other findings that, in the opinion of the Investigator, the Sponsor or Contract Research Organization (CRO) Medical Monitor, can indicate an unacceptable risk for the patient's participation in the study.

Sites / Locations

  • Emory University - Winship Cancer InstituteRecruiting
  • NEXT AustinRecruiting
  • NEXT OncologyRecruiting
  • Next VirginiaRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

ASN004 ascending doses

Arm Description

Patients will receive escalating doses of ASN004 to identify the best dose for further study.

Outcomes

Primary Outcome Measures

Determine the maximum tolerated dose of ASN004
The MTD will be determined by evaluating the number of subjects with treatment related adverse events (AEs) and DLTs.

Secondary Outcome Measures

Calculate the pharmacokinetic (PK) area under the plasma concentration of ASN004
Calculate the amount of ASN004 in the bloodstream
Calculate the maximum plasma concentration at steady state
Calculate the maximum amount of ASN004 in the bloodstream
Calculate the terminal elimination rate of ASN004
Calculate how fast ASN004 leaves the body
Change in the size of measurable tumor lesions
Change from baseline in the sum of the longest dimension in millimeters or each measurable lesion
Change in the status of non-measurable tumor lesions
Number of subjects that have resolution on non-measurable tumor lesions
Appearance of new tumor lesions
Number of subjects with new lesions

Full Information

First Posted
May 27, 2020
Last Updated
April 17, 2023
Sponsor
Kirilys Therapeutics Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04410224
Brief Title
Study of ASN004 in Patients With Advanced Solid Tumors
Acronym
ASN004
Official Title
An Open Label, Multicenter, Dose-Finding Clinical Phase 1 Study of ASN004 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy in Patients With Advanced Malignant Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 8, 2022 (Actual)
Primary Completion Date
March 31, 2025 (Anticipated)
Study Completion Date
March 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kirilys Therapeutics Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Participants in this study will receive ASN004 once every 3 weeks by intravenous infusion. The study will test various doses of ASN004 to find out the highest safe dose to test in future trials. Eligible subjects will be sequentially enrolled in cohorts at escalated doses.
Detailed Description
Eligible patients will be sequentially enrolled sequentially at escalating doses. Dose escalation decisions will be based on the review of clinical safety and pharmacokinetic (PD) and pharmacodynamics (PD) data and agreed upon by the Sponsor and investigators. The maximum tolerated dose (MTD) will have an estimated DLT rate of < 33%. Cohorts may be expanded at any dose level or at the MTD for further evaluation of safety, or PK parameters as required.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumor
Keywords
antibody-drug conjugate, immunoconjugate, General Solid Tumors

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Model Description
Escalating doses of ASN004
Masking
None (Open Label)
Allocation
N/A
Enrollment
43 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ASN004 ascending doses
Arm Type
Experimental
Arm Description
Patients will receive escalating doses of ASN004 to identify the best dose for further study.
Intervention Type
Drug
Intervention Name(s)
ASN004
Intervention Description
ASN004 is an antibody-drug conjugate for the treatment of advanced or metastatic solid tumors.
Primary Outcome Measure Information:
Title
Determine the maximum tolerated dose of ASN004
Description
The MTD will be determined by evaluating the number of subjects with treatment related adverse events (AEs) and DLTs.
Time Frame
first 21 days
Secondary Outcome Measure Information:
Title
Calculate the pharmacokinetic (PK) area under the plasma concentration of ASN004
Description
Calculate the amount of ASN004 in the bloodstream
Time Frame
First 63 days
Title
Calculate the maximum plasma concentration at steady state
Description
Calculate the maximum amount of ASN004 in the bloodstream
Time Frame
First 63 days
Title
Calculate the terminal elimination rate of ASN004
Description
Calculate how fast ASN004 leaves the body
Time Frame
First 63 days
Title
Change in the size of measurable tumor lesions
Description
Change from baseline in the sum of the longest dimension in millimeters or each measurable lesion
Time Frame
up to 1 year
Title
Change in the status of non-measurable tumor lesions
Description
Number of subjects that have resolution on non-measurable tumor lesions
Time Frame
Up to 1 year
Title
Appearance of new tumor lesions
Description
Number of subjects with new lesions
Time Frame
Up to 1 year
Other Pre-specified Outcome Measures:
Title
Correlate 5T4 oncofetal protein (5T4) expression and clinical efficacy
Description
Number of patients with 5T4 expression that have a complete response, partial response or prolonged stable disease when receiving ASN004.
Time Frame
Up to 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Provide written, voluntary informed consent prior to any -study specific procedure. Histologically confirmed diagnosis of advanced malignant solid tumor. All patients must agree to provide fresh or archival tumor tissue from the tumor lesion that has not been previously irradiated. Patients without archival tissue may only be enrolled if the patient consents to a screening biopsy and this procedure may be safely performed in the judgment of the Investigator. For Dose Expansion patients, eligible tumor histologies will be limited to those malignancies known to have highest expression of 5T4 including colorectal, breast, ovarian, lung, liver, and renal carcinomas. A maximum of 3 prior cytotoxic chemotherapy regimens is permitted for advanced disease. Failure of standard therapy or no standard therapy available. Presence of at least 1 measurable target lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 excluding previously irradiated lesions, bone metastasis, or pleural effusion as sole manifestations of disease. Dose escalation patients with evaluable (non-measurable) disease may be permitted to enroll with Medical Monitor approval. Age of at least 18 years old. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. A male patient must agree to use contraception as detailed in this protocol during the treatment period and for at least 3 months after the last dose of study treatment and refrain from donating sperm during this period. A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies. i. Not a woman of childbearing potential (WOCBP) OR ii. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 3 months after the last dose of study treatment. Adequate organ function. Patient is willing and able to comply with all protocol required visits and assessments. Exclusion Criteria Hematologic malignancies and lymphomas. Patients with known brain metastases unless the patient has a single lesion or multiple lesions whose sum of the longest diameter is ≤ 1 cm AND who are asymptomatic. Serious concurrent medical conditions. Patients with known history of left ventricular ejection fraction of < 50%.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Study Manager
Phone
James Chrisman
Email
jchrisman@kirilys.com
First Name & Middle Initial & Last Name or Official Title & Degree
Alison L Hannah, MD
Email
ahannah@kirilys.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alison L Hannah, MD
Organizational Affiliation
Kirilys Therapeutics Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Emory University - Winship Cancer Institute
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Manali A Bhave, MD
Facility Name
NEXT Austin
City
Austin
State/Province
Texas
ZIP/Postal Code
78758
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrae Vandross, MD
Phone
737-610-5200
First Name & Middle Initial & Last Name & Degree
Andrae Vandross
Facility Name
NEXT Oncology
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78240
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anthony Tolcher, M.D
Facility Name
Next Virginia
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alex Spira, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study of ASN004 in Patients With Advanced Solid Tumors

We'll reach out to this number within 24 hrs